Benitec Biopharma Limited Share Price Deutsche Boerse AG
Equities
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 145M 97.94M 89.47M 8.18B |
---|---|---|---|---|---|
Net income 2024 * | -34M -22.96M -20.97M -1.92B | Net income 2025 * | -42M -28.36M -25.91M -2.37B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 0 | Net cash position 2025 * | - 0 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.06
x | P/E ratio 2025 * |
-5.55
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.72% |
Managers | Title | Age | Since |
---|---|---|---|
Jerel Banks
CEO | Chief Executive Officer | 49 | 01/16/01 |
Peter Roelvink
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Megan Boston
CMP | Compliance Officer | 52 | 01/16/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
J. Buchi
BRD | Director/Board Member | 69 | 01/13/01 |
Edward Smith
BRD | Director/Board Member | 53 | 14/20/14 |
Peter Francis
BRD | Director/Board Member | 68 | 01/06/01 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 47.96B | |
+46.00% | 41.47B | |
+0.69% | 42.45B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |